Tunblad Karin, Lindbom Lars, McFadyen Lynn, Jonsson E Niclas, Marshall Scott, Karlsson Mats O
Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 75124, Uppsala, Sweden.
J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):503-26. doi: 10.1007/s10928-008-9099-z. Epub 2008 Nov 15.
To characterise the pharmacokinetics of dofetilide in patients and to identify clinically relevant parameter-covariate relationships. To investigate three different modelling strategies in covariate model building using dofetilide as an example: (1) using statistical criteria only or in combination with clinical irrelevance criteria for covariate selection, (2) applying covariate effects on total clearance or separately on non-renal and renal clearances and (3) using separate data sets for covariate selection and parameter estimation. Pooled concentration-time data (1,445 patients, 10,133 observations) from phase III clinical trials was used. A population pharmacokinetic model was developed using NONMEM. Stepwise covariate model building was applied to identify important covariates using the strategies described above. Inclusion and exclusion of covariates using clinical irrelevance was based on reduction in interindividual variability and changes in parameters at the extremes of the covariate distribution. Parametric separation of the elimination pathways was accomplished using creatinine clearance as an indicator of renal function. The pooled data was split in three parts which were used for covariate selection, parameter estimation and evaluation of predictive performance. Parameter estimations were done using the first-order (FO) and the first-order conditional estimation (FOCE) methods. A one-compartment model with first order absorption adequately described the data. Using clinical irrelevance criteria resulted in models containing less parameter-covariate relationships with a minor loss in predictive power. A larger number of covariates were found significant when the elimination was divided into a renal part and a non-renal part, but no gain in predictive power could be seen with this data set. The FO and FOCE estimation methods gave almost identical final covariate model structures with similar predictive performance. Clinical irrelevance criteria may be valuable for practical reasons since stricter inclusion/exclusion criteria shortens the run times of the covariate model building procedure and because only the covariates important for the predictive performance are included in the model.
表征多非利特在患者体内的药代动力学特征,并确定临床相关的参数-协变量关系。以多非利特为例,研究协变量模型构建中的三种不同建模策略:(1)仅使用统计标准或结合临床无关标准进行协变量选择;(2)将协变量效应应用于总清除率,或分别应用于非肾清除率和肾清除率;(3)使用单独的数据集进行协变量选择和参数估计。使用了来自III期临床试验的汇总浓度-时间数据(1445例患者,10133次观测)。使用NONMEM开发了群体药代动力学模型。采用逐步协变量模型构建方法,使用上述策略识别重要协变量。基于个体间变异性的降低以及协变量分布极端值处参数的变化,使用临床无关性进行协变量的纳入和排除。使用肌酐清除率作为肾功能指标,实现消除途径的参数分离。汇总数据分为三部分,分别用于协变量选择、参数估计和预测性能评估。使用一阶(FO)和一阶条件估计(FOCE)方法进行参数估计。具有一级吸收的单室模型充分描述了数据。使用临床无关性标准得到的模型包含较少的参数-协变量关系,预测能力略有损失。当将消除分为肾部分和非肾部分时,发现更多的协变量具有显著性,但该数据集的预测能力未见提高。FO和FOCE估计方法给出了几乎相同的最终协变量模型结构,预测性能相似。临床无关性标准可能出于实际原因而有价值,因为更严格的纳入/排除标准缩短了协变量模型构建程序的运行时间,并且因为模型中仅包含对预测性能重要的协变量。